Aridis Pharmaceuticals, Inc. (ARDS)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2022 | 1.25 Million USD | 108.95% |
| 2021 | -14 Million USD | -86.35% |
| 2020 | -7.51 Million USD | 64.03% |
| 2019 | -20.89 Million USD | 13.78% |
| 2018 | -24.23 Million USD | 3.42% |
| 2017 | -25.09 Million USD | -12.58% |
| 2016 | -22.29 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q1 | 2.62 Million USD | 109.41% |
| 2023 Q3 | 1.39 Million USD | -77.77% |
| 2023 Q2 | 6.27 Million USD | 138.99% |
| 2022 FY | 1.25 Million USD | 108.95% |
| 2022 Q3 | 12.19 Million USD | 82.48% |
| 2022 Q4 | 1.25 Million USD | -89.72% |
| 2022 Q1 | 512 Thousand USD | 103.66% |
| 2022 Q2 | 6.68 Million USD | 1205.27% |
| 2021 Q2 | -3.59 Million USD | 63.19% |
| 2021 FY | -14 Million USD | -86.35% |
| 2021 Q3 | -18.22 Million USD | -407.27% |
| 2021 Q4 | -14 Million USD | 23.12% |
| 2021 Q1 | -9.75 Million USD | -29.8% |
| 2020 Q4 | -7.51 Million USD | -36.75% |
| 2020 Q3 | -5.49 Million USD | 50.46% |
| 2020 Q2 | -11.09 Million USD | 32.02% |
| 2020 Q1 | -16.32 Million USD | 21.88% |
| 2020 FY | -7.51 Million USD | 64.03% |
| 2019 FY | -20.89 Million USD | 13.78% |
| 2019 Q4 | -20.89 Million USD | -20.58% |
| 2019 Q3 | -17.33 Million USD | -103.43% |
| 2019 Q2 | -8.51 Million USD | 47.77% |
| 2019 Q1 | -16.31 Million USD | 32.7% |
| 2018 Q2 | -13.47 Million USD | 33.93% |
| 2018 FY | -24.23 Million USD | 3.42% |
| 2018 Q4 | -24.23 Million USD | 28.88% |
| 2018 Q3 | -34.07 Million USD | -152.98% |
| 2018 Q1 | -20.38 Million USD | 18.76% |
| 2017 Q4 | -25.09 Million USD | 0.0% |
| 2017 FY | -25.09 Million USD | -12.58% |
| 2016 FY | -22.29 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| America Great Health | 1.81 Million USD | 30.952% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | 132.87% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 96.107% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 233.546% |
| Better Therapeutics, Inc. | -860 Thousand USD | 245.814% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 105.272% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -281.804% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | 72.56% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 121.535% |
| Evelo Biosciences, Inc. | 3.19 Million USD | 60.788% |
| Evolutionary Genomics, Inc. | 3.16 Million USD | 60.4% |
| Finch Therapeutics Group, Inc. | 5 Million USD | 74.93% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 99.064% |
| Innovation1 Biotech Inc. | 179.15 Thousand USD | -599.972% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 89.837% |
| Molecular Templates, Inc. | 707 Thousand USD | -77.369% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | -186.011% |
| NexImmune, Inc. | -3.13 Million USD | 140.017% |
| Orgenesis Inc. | 21.78 Million USD | 94.243% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | 52.064% |
| Point of Care Nano-Technology, Inc. | -498.00 USD | 251907.229% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 126.621% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 1106.623% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 98.869% |
| Statera Biopharma, Inc. | 14.41 Million USD | 91.302% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 116.509% |
| Trevena, Inc. | 2.25 Million USD | 44.464% |
| Vaxxinity, Inc. | 10.13 Million USD | 87.623% |
| Vaccinex, Inc. | -1.28 Million USD | 197.36% |
| Vicapsys Life Sciences, Inc. | 344.44 Thousand USD | -264.063% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 90.528% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -1642.586% |